Biotech Top Stocks to Watch: VVUS, SQNM, ABIO, ARNA, DNDN

Los Angelas, CA -- (SBWIRE) -- 02/07/2013 -- VIVUS, Inc. (NASDAQ:VVUS) shares climbed 3.78% to $13.45. The company, on Jan. 7, said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended December 21 compared with the preceding four weeks, well above industry forecasts. The drugmaker said it shipped 12,978 prescriptions of Qsymia in the latest period, up from 7,749 in the four weeks ended November 23. New Qsymia prescriptions totaled 5,229 in the latest period.

How Should Investors React To VVUS Now? Find Out Here

Sequenom, Inc. (NASDAQ:SQNM) surged 3.66%, extending gains after the news that CMM’s MaterniT21 PLUS LDT will now report on Gender-Specific Chromosomal abnormalities. Manufactures DNA detection and sequencing equipment. The Company's two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository.

Will New Regulations Weigh over SQNM Revenue Stream? Find Out Here

Arca Biopharma Inc (NASDAQ:ABIO) was among biggest gainers in the biotechnology industry on Wednesday. The stock closed 13.04% higher after articles in Inaugural Issue of JACC: Heart Failure highlighted unmet medical need in treatment of heart failure patients with Atrial Fibrillation. ARCA biopharma, Inc. is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases.

What Are ABIO’s Charts Signaling For Traders? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) moved up +1.04% and closed at $8.72 in the last trading session with the overall traded volume of 5.65 million shares. ARNA has outstanding shares of 217.29 million with the total market cap of 1.89 billion. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs).

Is ARNA a Solid Investment at These Levels? Find Out Here

Dendreon Corporation (NASDAQ:DNDN) reported the gain of +7.95% and closed at $6.65 with the overall traded volume of 13.37 million shares, more than the average volume of 7.15 million. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics.

Can DNDN Continue To Move Higher? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com